HUP0400117A3 - Polymorphs of 2-methyl-2-[4-({[-4methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-carbonyl]-amino}-methyl)-phenoxy]-propionic acid, process for their preparation, their use and pharmaceurical compositions containing them - Google Patents

Polymorphs of 2-methyl-2-[4-({[-4methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-carbonyl]-amino}-methyl)-phenoxy]-propionic acid, process for their preparation, their use and pharmaceurical compositions containing them

Info

Publication number
HUP0400117A3
HUP0400117A3 HU0400117A HUP0400117A HUP0400117A3 HU P0400117 A3 HUP0400117 A3 HU P0400117A3 HU 0400117 A HU0400117 A HU 0400117A HU P0400117 A HUP0400117 A HU P0400117A HU P0400117 A3 HUP0400117 A3 HU P0400117A3
Authority
HU
Hungary
Prior art keywords
methyl
pharmaceurical
4methyl
polymorphs
thiazol
Prior art date
Application number
HU0400117A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HUP0400117A2 publication Critical patent/HUP0400117A2/hu
Publication of HUP0400117A3 publication Critical patent/HUP0400117A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
HU0400117A 2001-05-31 2002-05-29 Polymorphs of 2-methyl-2-[4-({[-4methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-carbonyl]-amino}-methyl)-phenoxy]-propionic acid, process for their preparation, their use and pharmaceurical compositions containing them HUP0400117A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113232.3A GB0113232D0 (en) 2001-05-31 2001-05-31 Chemical process
PCT/EP2002/005884 WO2002096893A1 (en) 2001-05-31 2002-05-29 Process for preparing a thialzole ppar-ligand and polymorphs thereof

Publications (2)

Publication Number Publication Date
HUP0400117A2 HUP0400117A2 (hu) 2005-03-29
HUP0400117A3 true HUP0400117A3 (en) 2005-09-28

Family

ID=9915637

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400117A HUP0400117A3 (en) 2001-05-31 2002-05-29 Polymorphs of 2-methyl-2-[4-({[-4methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-carbonyl]-amino}-methyl)-phenoxy]-propionic acid, process for their preparation, their use and pharmaceurical compositions containing them

Country Status (22)

Country Link
US (1) US7244849B2 (enExample)
EP (1) EP1395572B1 (enExample)
JP (1) JP2004532265A (enExample)
KR (1) KR20040007631A (enExample)
CN (1) CN1551871A (enExample)
AT (1) ATE315556T1 (enExample)
AU (1) AU2002317764B2 (enExample)
BR (1) BR0209892A (enExample)
CA (1) CA2448101A1 (enExample)
CO (1) CO5540298A2 (enExample)
CZ (1) CZ20033256A3 (enExample)
DE (1) DE60208682T2 (enExample)
ES (1) ES2256493T3 (enExample)
GB (1) GB0113232D0 (enExample)
HU (1) HUP0400117A3 (enExample)
IL (1) IL158641A0 (enExample)
MX (1) MXPA03010943A (enExample)
NO (1) NO20035313L (enExample)
NZ (1) NZ529486A (enExample)
PL (1) PL367114A1 (enExample)
WO (1) WO2002096893A1 (enExample)
ZA (1) ZA200308570B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1517882A1 (en) 2002-06-19 2005-03-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
EP1734930A2 (en) * 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
CN101400663A (zh) * 2006-01-10 2009-04-01 史密丝克莱恩比彻姆公司 {2-甲基-4-[4-甲基-2-(4-三氟甲基苯基)噻唑-5-基甲硫基]苯氧基}-乙酸的多晶型
US20140112992A1 (en) * 2011-06-06 2014-04-24 Hetero Research Foundation Process for febuxostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1395572A1 (en) 2004-03-10
ES2256493T3 (es) 2006-07-16
BR0209892A (pt) 2004-06-08
CZ20033256A3 (en) 2004-04-14
DE60208682D1 (de) 2006-04-06
EP1395572B1 (en) 2006-01-11
KR20040007631A (ko) 2004-01-24
JP2004532265A (ja) 2004-10-21
NZ529486A (en) 2005-12-23
DE60208682T2 (de) 2006-08-24
CO5540298A2 (es) 2005-07-29
IL158641A0 (en) 2004-05-12
AU2002317764B2 (en) 2005-01-06
GB0113232D0 (en) 2001-07-25
PL367114A1 (en) 2005-02-21
US7244849B2 (en) 2007-07-17
WO2002096893A1 (en) 2002-12-05
ZA200308570B (en) 2005-02-03
CA2448101A1 (en) 2002-12-05
HUP0400117A2 (hu) 2005-03-29
NO20035313L (no) 2003-12-09
ATE315556T1 (de) 2006-02-15
US20040242657A1 (en) 2004-12-02
CN1551871A (zh) 2004-12-01
MXPA03010943A (es) 2004-02-27
NO20035313D0 (no) 2003-11-28

Similar Documents

Publication Publication Date Title
HUP0103988A3 (en) N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfonamides, process for their preparation, their use and pharmaceutical compositions containing them
HUP0303128A3 (en) Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it
IL175933A (en) Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt, a pharmaceutical composition comprising the same and a process for preparing the same
HUP0303398A3 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same
AU2001262723A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
IL158631A (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives, process for their preparation, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of pain, anxiety or functional gastrointestinal disorders
TWI370131B (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
HUP0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HUP0301811A3 (en) Compounds having hypolipedemic and hypocholesteremic activities, process for their prreparation and pharmaceutical compositions containing them and their use, intermediates
HUP0401201A3 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
HUP0400117A3 (en) Polymorphs of 2-methyl-2-[4-({[-4methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-carbonyl]-amino}-methyl)-phenoxy]-propionic acid, process for their preparation, their use and pharmaceurical compositions containing them
HUP0204563A3 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
FR2848428B1 (fr) Composition cosmetique et procede pour le traitement des matieres keratiniques, comprenant un compose photodimerisable
IL170314A (en) 4 - (3 -(2 - phenyl - oxazol - 4 - ylmethoxy) - cyclohexyloxy) - butane acid derivatives and related compounds, pharmaceutical compositions comprising them and use thereof
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
NO20010522L (no) Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
SI1170281T1 (sl) Nove spojine 1,1-in 1,2-disubstituirani ciklopropani, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
IL136231A (en) Process and intermediate for preparing cis-1-(2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)- phenoxy] ethyl) pyrrolidine
IL176523A0 (en) Ascorbic acid compounds, methods of synthesis and application use thereof
WO2004024060A3 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
WO2002053537A8 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
PL362650A1 (en) Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
HUP0401115A3 (en) 4-(benzylideneamino)-3-(methylsulfanyl)-4h-[1,2,4]triazin-5-one derivatives having a pde iv-inhibiting and tnf-antagonistic action for the treatment of heart diseases and allergies, process for their preparation and pharmaceutical compositions ...
IL157061A0 (en) Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof